Xia-Gibbs syndrome (OMIM 615829) was mentioned for the first time by Xia et al. [2014] after analysis of parent-offspring trios of 4 probands with DD, hypotonia, mild dysmorphic features, sleep apnea, and other symptoms, finding 3 new allelic variants in the ADHC1 (AT hook DNA-binding motif containing 1) gene likely to be pathogenic; it was the first report in genome databases. Yang et al. [2015] reported 6 frameshifts or nonsense deleterious de novo variants and 1 recurrent variant in the same gene, associated with expressive language delay, hypotonia, and sleep apnea. Recently, Bosch et al. [2016] identified a de novo variant in an older patient with a history of DD and speech delay as well as characteristic facies. Previously, a de novo missense variant in a case of schizophrenia [Guipponi et al., 2014] and a de novo balanced translocation with a breakpoint in the AHDC1 intron 1 in a boy with bicuspid aortic valve, aortic coarctation, patent ductus arteriosus, and DD/ID have been reported in this gene [Quintero-Rivera et al., 2015] . Several large CNV deletions including the AHDC1 gene have been described in pediatric patients with DD/ID [Itsara et al., 2009; Cooper et al., 2011; Coe et al., 2014] . Although due to the large size of the deletions, it is uncertain whether AHDC1 is the only gene contributing to the neurodevelopmental phenotype. Xia et al. [2014] proposed that AHDC1 -associated ID is due to a dominant-negative mechanism, given the autosomal-dominant inheritance and the single coding exon of this gene.
The AHDC1 gene located in chromosome 1p36.11 encodes a protein of 1,603 amino acids, consisting of 7 exons with only 1 coding exon (exon 6), containing 2 AT-hooks, which likely function in DNA binding. AT-hook motifs are known as auxiliary protein motifs that cooperate with other DNA-binding activities and facilitate DNA structure changes [Aravind and Landsman, 1998 ]. The AHDC1 gene is part of the CBX family of proteins associated with human chromodomain-containing Polycomb proteins [Vandamme et al., 2011] . In vivo assays have demonstrated that AHDC1 interacts with several nuclear proteins involved in epigenetic regulation during development [Vandamme et al., 2011] , mainly in neural sites and neuron proteins for transport [Uhlén et al., 2015] . In mice, Ahdc1 is expressed at embryonic day E11.5 and E16.5 in the developing brain [Quintero-Rivera et al., 2015] , suggesting that AHDC1 may be involved in early brain development. In this study, we described the first Colombian patient with Xia-Gibbs syndrome, with a new mutation in the AHDC1 gene identified by WES and compared the 12 cases reported in the literature to better understand the clinical phenotype and the association with the AHDC1 gene.
Patient and Methods

Case Report
The 8-year-old Colombian girl is the first child born at term to 27-year-old nonconsanguineous parents after prolonged labor and perinatal hypoxia, with an Apgar score of 6 at 10 min. The child was admitted to the neonatal intensive care unit requiring mechanical ventilation for 27 days. Clinical follow-up showed hypotonia and DD (head control at 7 months, sitting at 12 months, standing at 24 months, walking at 28 months, and currently speaking only 2 words) with dysmorphic features including midfacial hypoplasia, hypertelorism, micrognathia, epicanthic fold, prominent teeth, upslanting palpebral fissures ( Fig. 1 ) , and laryngoma- ( Fig. 1 ) . The girl's karyotype, microarray, and metabolic tests were normal.
Molecular Analysis
WES was performed using Illumina HiSeq platform (overall performance of 90% exome coverage at 40× depth) identifying a new mutation in AHDC1 (c.2030_2030delG; p.Gly677AlafsX52) verified by Sanger sequencing and absent in both maternal and paternal DNA. It was therefore interpreted as a de novo event that results in a frameshift of the AHDC1 open reading frame and is predicted to cause a premature termination codon after 52 amino acids. Predicted truncating mutations in AHDC1 are absent in the genome mutation databases dbSNP and ExAC. The pathogenic effect of the described mutation in AHDC1 was predicted by the bioinformatic tools PolyPhen-2 (prediction "probably damaging" -score of 0.958) [Adzhubei et al., 2010] , MutationTaster (prediction "disease causing") [Schwarz et al., 2014] , and SNPs&GO (RI = 8 Effect = neutral) [Calabrese et al., 2009] . Furthermore, glycine is a conserved amino acid between species; therefore, any change in this amino acid can generate alterations of the protein structure.
Discussion
Here, we report a proband with DD and dysmorphic facial features due to a frameshift mutation in AHDC1 , which was discovered by WES. To date, 12 individuals with AHDC1 mutations have been reported in the literature. Developmental histories of patients evidenced that all had delayed speech and psychomotor delay; most individuals had mild dysmorphic facial features that could be seen at a young age and had a history of sleep disturbance because of anomalies of the upper airway structure.
The independent occurrence of 12 de novo mutational events at this locus in unrelated individuals with similar phenotypes is highly unlikely, suggesting that mutations in AHDC1 cause this complex disorder, which has not been previously reported in the literature since Xia et al. [2014] . It is remarkable that all cases were detected by WES after several genetic tests. Clinical features of the reported cases of Xia et al. [2014] , Yang et al. [2015] , and Bosch et al. [2016] compared with the clinical presentation of our case are summarized in Table 1 . Xia et al. [2014] proposed that AHDC1 -associated ID is due to a dominant-negative mechanism, given the autosomal-dominant inheritance and the single coding exon of this gene . This results in an insufficient dosage of encoded protein which would sever the link between DNA damage response and proper brain development [Quintero-Rivera et al., 2015] . This is based on a model in which the protein encoded by the gene with the gene dosage imbalance or mutation affects the bindings to other protein(s) to form a functional complex which may lead to the formation of inactive complexes [Poot et al., 2011] . Although there are no functional or computational studies of these proteins, we speculate that AHDC1 variants may interrupt protein translation, possibly disrupting the interaction with other proteins important for brain development and function.
WES has proven to be an important tool to improve our ability to diagnose patients with heterogeneous diseases; especially, the expanded use of WES has led us to find new genes causing diseases and new diseases caused by genes. Variants in AHDC1 should be validated with in vivo and in vitro assays to understand the mechanisms of the genotype/phenotype relationship.
